Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 2/20 | 0.64 |
| ▸ | PRKCA | P17252 | 3/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396287 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL333509 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL128511 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL332921 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL2831338 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL333109 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL2835498 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL2396865 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL33706 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 | |
| SCHEMBL42627 | 1.00 | MAPT (0.76) | MAPTLMNAALDH1A1KDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107667108-B | Naphthyridine compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-05-12 | — | — | CN | claimed |
| US-7833957-B2 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2010-11-16 | — | — | US | claimed |
| US-20060138399-A1 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2006-06-29 | — | — | US | claimed |
| CN-1678961-A | Removing solution | DAIKIN IND LTD (JP) | 2005-10-05 | — | — | CN | claimed |
| EP-1536291-A1 | REMOVING SOLUTION | Daikin Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | claimed |
| EP-4583177-A1 | METHOD OF MANUFACTURING ELECTRODE, COMPOSITE ELECTRODE, ELECTROCHEMICAL ELEMENT, AND APPARATUS FOR MANUFACTURING ELECTRODE | Ricoh Company, Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | EXCELLA BIOSCIENTIFIC LTD (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250075143-A1 | BIOLUBRICANTS SYNTHESIS FROM OIL/FAT OZONIZED-DERIVED PRODUCTS | PURDUE RESEARCH FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20240318085-A1 | BIOFUELS FROM OXIDATION PRODUCTS OF OLEIC OIL | PURDUE RESEARCH FOUNDATION | 2024-09-26 | — | — | US | disclosed |
| US-20240269101-A1 | COMPOSITIONS COMPRISING MEDIUM ODD CHAIN LIPIDS WITH MULTIFUNCTIONAL ACTIVITY TO PREVENT AND TREAT SKIN INFLAMMATION AND AGING | EXCELLA BIOSCIENTIFIC LTD (IL) | 2024-08-15 | — | — | US | disclosed |
| EP-4362128-A1 | LIQUID COMPOSITION, METHOD FOR PRODUCING LIQUID COMPOSITION, ELECTRODE, ELECTRODE PRODUCTION APPARATUS, AND METHOD FOR PRODUCING ELECTRODE | Ricoh Company, Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20230265268-A1 | THERMOPLASTIC ELASTOMER COMPOSITION | POLYMAX THERMOPLASTIC ELASTOMERS, LLC | 2023-08-24 | — | — | US | disclosed |
| US-20110232528-A1 | OILY INKJET INK | RISO KAGAKU CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7833957-B2 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080188504-A1 | Process for Preparing Pure Amorphous Rosuvastatin Calcuim | LEK D.D (SI) | 2008-08-07 | — | — | US | disclosed |
| US-20060138399-A1 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| CN-1678961-A | Removing solution | DAIKIN IND LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1536291-A1 | REMOVING SOLUTION | Daikin Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1200454-A1 | BISPLATINUM COMPLEXES ACTIVE THROUGH THE ORAL ROUTE | Novuspharma S.p.A. (IT) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009149-A1 | BISPLATINUM COMPLEXES ACTIVE THROUGH THE ORAL ROUTE | NOVUSPHARMA S.P.A. (IT) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188504-A1 | Process for Preparing Pure Amorphous Rosuvastatin Calcuim | PCSK9, HMGCR, CARM1 | MAPT 118/4885LMNA 440/4885ALDH1A1 3683/4885 |
| US-20240269101-A1 | COMPOSITIONS COMPRISING MEDIUM ODD CHAIN LIPIDS WITH MULTIFUNCTIONAL ACTIVITY TO PREVENT AND TREAT SKIN INFLAMMATION AND AGING | DGAT2, DAGLA, DGAT1 | MAPT 2793/4885LMNA 2190/4885ALDH1A1 1148/4885 |
| US-20250186319-A1 | ANAPLEROTIC COMPOSITIONS AND USES THEREOF | OAT, PC, ACAT1 | MAPT 2101/4885LMNA 2416/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.